Companies · Pharmaceuticals
ATLANTA · Pharmaceuticals
Diligence memoA one-page analyst read on Surterra Holdings, Inc./DE — recommendation, valuation, rhythm, risks.→Surterra Holdings, Inc./DE looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Surterra Holdings, Inc./DE behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Surterra Holdings, Inc./DE is one of 1613 Pharmaceuticals companies tracked from ATLANTA. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 97% of sector peers (real $). Modeled value above 99% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 11.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Concordia International Corp. | Series D+ | $228.0M | $8.1B | 1.82× |
| Surterra Holdings, Inc./DE this company | Series D+ | $230.4M | $5.8B | 1.32× |
| Ironwood Pharmaceuticals Inc | Series D+ | $350.0M | $5.3B | 1.20× |
| Melinta Therapeutics, Inc. /New/ | Series D+ | $346.8M | $4.9B | 1.10× |
| Beam Therapeutics Inc. | Series D+ | $218.6M | $4.8B | 1.08× |
| Tris Pharma, Inc. | Series D+ | $125.0M | $4.4B | 1.00× |
| Ardelyx, Inc. | Series D+ | $210.4M | $3.9B | 0.88× |
| Tesaro, Inc. | Series D+ | $255.0M | $1.8B | 0.40× |
| Orexigen Therapeutics, Inc. | Series D+ | $274.6M | $1.8B | 0.40× |
| Strongbridge Biopharma plc | Series D+ | $220.6M | $1.2B | 0.28× |
| RxBio Holdings, Inc. | Series D+ | $128.7M | $12.0M | 0.00× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $65.0M | 2018-07-20 | $433.3M | $2.3B | 90% |
| Series C | $54.6M | 2018-10-16 | $364.2M | $1.9B | 90% |
| Series D+ | $165.4M | 2018-10-16 | $1.4B | $5.8B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Jason Jacob Becker | — | 2 other | 2018-10 |
| Jason H Becker | — | 1 other | 2018-10 |
| Robert Jacob Bergmann | — | 1 other | 2018-10 |
| Tom Jacob Venables | — | 1 other | 2018-10 |
| Andrew H. Allen | — | — | 2018-10 |
| Andrew Jacob Allen | — | — | 2018-10 |
| James H. Whitcomb | — | — | 2018-07 |
| Jay H. Holmes | — | — | 2018-10 |
| Jay Jacob Holmes | — | — | 2018-10 |
| Tim H. Vining | — | — | 2018-10 |
| Tim Jacob Vining | — | — | 2018-10 |
| Tom H. Venables | — | — | 2018-10 |
| William H. Wrigley Jr. | — | — | 2018-10 |
| William Jacob Wrigley Jr. | — | — | 2018-10 |
Surterra Holdings, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Surterra Holdings, Inc. | Other | Series C | $98.0M | $1.4B | network3 shared operators |
| Concordia International Corp. | Pharmaceuticals | Series D+ | $228.0M | $8.1B | same sector · same stage |
| Strongbridge Biopharma plc | Pharmaceuticals | Series D+ | $220.6M | $1.2B | same sector · same stage |
| Cingulate Inc. | Pharmaceuticals | Series D+ | $220.0M | $5.4B | same sector · same stage |
| Beam Therapeutics Inc. | Pharmaceuticals | Series D+ | $218.6M | $4.8B | same sector · same stage |
| NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | Series D+ | $218.1M | $913.2M | same sector · same stage |
| Verona Pharma plc | Pharmaceuticals | Series D+ | $244.7M | $7.0B | same sector · same stage |
| MAPS Public Benefit Corp | Pharmaceuticals | Series D+ | $215.1M | $2.9B | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Surterra Holdings, Inc. | Other | Series C | $1.4B | 85% |
| MedAvail Holdings, Inc. | Pharmaceuticals | Series B | $679.3M | 79% |
| Receptor Holdings, Inc. | Pharmaceuticals | Series B | $141.0M | 78% |
| Enumeral Biomedical Holdings, Inc. | Pharmaceuticals | Series B | $22.7M | 78% |
| ADARx Pharmaceuticals, Inc. | Pharmaceuticals | Series D+ | $2.8B | 78% |
| Sator Holdings LLC | Pharmaceuticals | Pre-Seed | $11.8M | 78% |
| ProVet Investment Holdings, LLC | Pharmaceuticals | Series A | $11.2M | 78% |
| Regenacy Pharmaceuticals, Inc. | Pharmaceuticals | Series B | $142.6M | 78% |
See where Surterra Holdings, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Surterra Holdings, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.